EE200300408A - Aktiivsete valkude saagise suurendamine - Google Patents
Aktiivsete valkude saagise suurendamineInfo
- Publication number
- EE200300408A EE200300408A EEP200300408A EEP200300408A EE200300408A EE 200300408 A EE200300408 A EE 200300408A EE P200300408 A EEP200300408 A EE P200300408A EE P200300408 A EEP200300408 A EE P200300408A EE 200300408 A EE200300408 A EE 200300408A
- Authority
- EE
- Estonia
- Prior art keywords
- increasing
- yield
- active proteins
- proteins
- preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Measurement Of Radiation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27103301P | 2001-02-23 | 2001-02-23 | |
PCT/US2002/005645 WO2002068455A2 (en) | 2001-02-23 | 2002-02-22 | Efficient recovery of correctly refolded proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200300408A true EE200300408A (et) | 2003-12-15 |
Family
ID=23033913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300408A EE200300408A (et) | 2001-02-23 | 2002-02-22 | Aktiivsete valkude saagise suurendamine |
Country Status (21)
Country | Link |
---|---|
US (2) | US7157557B2 (et) |
EP (1) | EP1366062B1 (et) |
JP (1) | JP2005505494A (et) |
KR (1) | KR20040052481A (et) |
CN (1) | CN1547586A (et) |
AT (1) | ATE517909T1 (et) |
AU (1) | AU2002255600B2 (et) |
BG (1) | BG108087A (et) |
CA (1) | CA2438094C (et) |
CZ (1) | CZ20032208A3 (et) |
EE (1) | EE200300408A (et) |
ES (1) | ES2370235T3 (et) |
HK (1) | HK1059267A1 (et) |
HU (1) | HUP0303246A2 (et) |
IL (1) | IL157446A0 (et) |
MX (1) | MXPA03007563A (et) |
PL (1) | PL374045A1 (et) |
RU (1) | RU2316563C2 (et) |
SK (1) | SK10472003A3 (et) |
WO (1) | WO2002068455A2 (et) |
ZA (1) | ZA200305909B (et) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03007563A (es) * | 2001-02-23 | 2003-12-11 | Immunex Corp | Recuperacion incrementada de proteinas activas. |
EP3192872A1 (en) | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
EP1805205A1 (en) * | 2004-10-22 | 2007-07-11 | Amgen Inc. | Methods for refolding polypeptides |
US7928205B2 (en) * | 2004-10-22 | 2011-04-19 | Amgen Inc. | Methods for refolding of recombinant antibodies |
JP2008528006A (ja) * | 2005-01-28 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
CA2607663C (en) | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
EP1893632B1 (en) * | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
JP5036727B2 (ja) | 2005-12-22 | 2012-09-26 | ジェネンテック, インコーポレイテッド | ヘパリン結合タンパク質の組み換え体産生 |
WO2007102946A2 (en) | 2006-01-23 | 2007-09-13 | Amgen Inc. | Crystalline polypeptides |
BRPI0713252C1 (pt) | 2006-07-14 | 2021-05-25 | Genentech Inc | processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado |
US7705132B2 (en) | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
PT3597659T (pt) | 2007-07-09 | 2023-04-04 | Genentech Inc | Prevenção da redução de ligações de dissulfureto durante a produção recombinante de polipéptidos |
EP2197911A2 (en) * | 2007-09-14 | 2010-06-23 | Amgen Inc. | Homogeneous antibody populations |
AU2010270986B2 (en) | 2009-06-22 | 2014-05-22 | Amgen Inc. | Refolding proteins using a chemically controlled redox state |
ES2862580T5 (es) | 2009-06-25 | 2024-06-13 | Amgen Inc | Procesos de purificación por captura para proteínas expresadas en un sistema no de mamífero |
US9005926B2 (en) | 2009-10-02 | 2015-04-14 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
RU2012127383A (ru) * | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
PL2673296T3 (pl) | 2011-02-07 | 2019-03-29 | Cerenis Therapeutics Holding Sa | Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania |
WO2012170938A1 (en) | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
KR20200044138A (ko) | 2011-06-24 | 2020-04-28 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
WO2013106589A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
US9353165B2 (en) | 2012-07-25 | 2016-05-31 | Grifols, S.A. | Purification of cell culture derived alpha1 protease inhibitor |
CN104508133B (zh) | 2012-08-02 | 2018-04-20 | 弗·哈夫曼-拉罗切有限公司 | 用于产生单体和多聚体分子的方法及其用途 |
CN110051823A (zh) | 2012-09-11 | 2019-07-26 | 科荣生生物科学公司 | 高纯度和优异产量的正确折叠的依那西普 |
BR112015021495A2 (pt) | 2013-03-08 | 2017-07-18 | Genzyme Corp | fabricação contínua integrada de substâncias de droga de proteína terapêutica |
TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
WO2018075818A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
US11369703B2 (en) | 2018-08-31 | 2022-06-28 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
AU2019356564A1 (en) | 2018-10-11 | 2021-04-29 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
WO2022140389A1 (en) | 2020-12-22 | 2022-06-30 | Amgen Inc. | Cell culture method |
CN118047854A (zh) * | 2024-02-26 | 2024-05-17 | 武汉鹰达生物科技有限公司 | 一种人载脂蛋白a-i的分离纯化方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453363A (en) * | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
EP0293785A3 (en) | 1987-05-29 | 1990-05-02 | Oncogen Limited Partnership | Cloning and expression of simian transforming growth factor-ss1 |
US4970067A (en) * | 1988-12-12 | 1990-11-13 | Helene Curtis, Inc. | Method and composition to condition hair and impart semi-permanent hair set retention properties |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
AU648214B2 (en) * | 1991-12-31 | 1994-04-14 | Lucky Limited | Recombinant gene coding for human alpha interferon and expression vector thereof, etc. |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
EP0663009A1 (en) * | 1993-08-04 | 1995-07-19 | Novartis AG | High molecular weight desulphatohirudin |
US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
WO1995032216A1 (en) * | 1994-05-25 | 1995-11-30 | University Of Nebraska Board Of Regents | Biologically active glycoprotein hormones produced in procaryotic cells |
CZ283219B6 (cs) * | 1994-07-22 | 1998-02-18 | F. Hoffmann-La Roche Ag | Použití chimerního proteinu vázajícího TNF pro výrobu farmaceutického prostředku k ošetřování autoimunních nemocí |
US5879673A (en) * | 1996-01-25 | 1999-03-09 | Genentech, Inc. | Administration of thrombopoietin on a single day only |
US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
FR2803303B1 (fr) * | 2000-01-04 | 2002-05-10 | Aventis Pasteur | Glycoproteine d'enveloppe du vih modifiee chimiquement |
MXPA03007563A (es) * | 2001-02-23 | 2003-12-11 | Immunex Corp | Recuperacion incrementada de proteinas activas. |
-
2002
- 2002-02-22 MX MXPA03007563A patent/MXPA03007563A/es active IP Right Grant
- 2002-02-22 PL PL02374045A patent/PL374045A1/xx unknown
- 2002-02-22 AT AT02725004T patent/ATE517909T1/de not_active IP Right Cessation
- 2002-02-22 CZ CZ20032208A patent/CZ20032208A3/cs unknown
- 2002-02-22 HU HU0303246A patent/HUP0303246A2/hu unknown
- 2002-02-22 SK SK1047-2003A patent/SK10472003A3/sk not_active Application Discontinuation
- 2002-02-22 EE EEP200300408A patent/EE200300408A/et unknown
- 2002-02-22 WO PCT/US2002/005645 patent/WO2002068455A2/en active Application Filing
- 2002-02-22 JP JP2002567965A patent/JP2005505494A/ja active Pending
- 2002-02-22 CA CA2438094A patent/CA2438094C/en not_active Expired - Fee Related
- 2002-02-22 KR KR10-2003-7010687A patent/KR20040052481A/ko not_active Application Discontinuation
- 2002-02-22 ES ES02725004T patent/ES2370235T3/es not_active Expired - Lifetime
- 2002-02-22 EP EP02725004A patent/EP1366062B1/en not_active Expired - Lifetime
- 2002-02-22 US US10/080,471 patent/US7157557B2/en not_active Expired - Lifetime
- 2002-02-22 IL IL15744602A patent/IL157446A0/xx unknown
- 2002-02-22 AU AU2002255600A patent/AU2002255600B2/en not_active Expired
- 2002-02-22 CN CNA02805444XA patent/CN1547586A/zh active Pending
- 2002-02-22 RU RU2003127830/13A patent/RU2316563C2/ru active
-
2003
- 2003-07-31 ZA ZA200305909A patent/ZA200305909B/en unknown
- 2003-08-13 BG BG108087A patent/BG108087A/bg unknown
-
2004
- 2004-01-30 HK HK04100666.9A patent/HK1059267A1/xx not_active IP Right Cessation
-
2006
- 2006-11-22 US US11/603,544 patent/US7544784B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
MXPA03007563A (es) | 2003-12-11 |
ES2370235T3 (es) | 2011-12-13 |
PL374045A1 (en) | 2005-09-19 |
US7157557B2 (en) | 2007-01-02 |
SK10472003A3 (sk) | 2004-03-02 |
WO2002068455A2 (en) | 2002-09-06 |
IL157446A0 (en) | 2004-03-28 |
CA2438094A1 (en) | 2002-09-06 |
AU2002255600B2 (en) | 2008-01-24 |
HUP0303246A2 (hu) | 2003-12-29 |
CA2438094C (en) | 2011-10-11 |
BG108087A (bg) | 2005-04-30 |
US7544784B2 (en) | 2009-06-09 |
EP1366062B1 (en) | 2011-07-27 |
US20070270577A1 (en) | 2007-11-22 |
RU2003127830A (ru) | 2005-04-10 |
ZA200305909B (en) | 2004-06-04 |
KR20040052481A (ko) | 2004-06-23 |
JP2005505494A (ja) | 2005-02-24 |
US20020182665A1 (en) | 2002-12-05 |
ATE517909T1 (de) | 2011-08-15 |
HK1059267A1 (en) | 2004-06-25 |
RU2316563C2 (ru) | 2008-02-10 |
WO2002068455A3 (en) | 2003-09-18 |
EP1366062A2 (en) | 2003-12-03 |
CN1547586A (zh) | 2004-11-17 |
CZ20032208A3 (cs) | 2004-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300408A (et) | Aktiivsete valkude saagise suurendamine | |
NO2020016I1 (no) | efmoroktokog alfa - forlenget SPC | |
DK1641483T3 (da) | Fusionsproteiner | |
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
DE60037450D1 (de) | Funf-helix protein | |
EP2298331A3 (en) | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins | |
EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
ATE408631T1 (de) | Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion | |
DK1368372T3 (da) | Peptid med affinitet til det virale gp120-protein samt anvendelse deraf | |
DK1412503T3 (da) | Et fusionsprotein | |
EA200500624A1 (ru) | Промотор для il-18bp, его получение и применение | |
WO2003022883A3 (de) | Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems | |
DE60211227D1 (de) | Androgenrezeptor-Komplex assoziiertes Protein | |
AU2013245463B2 (en) | Immunoglobulin Chimeric Monomer-Dimer Hybrids | |
AU2003280359A1 (en) | Phosphoamidase assay | |
WO2003048320A3 (en) | Novel motor protein of p. falciparum and methods for its use |